HSCI research inspires startup

November 16, 2016

Startup Magenta Therapeutics licences technologies from Harvard, MGH, and Boston Children's that could transform treatment of blood diseases and immune disorders

Harvard University has completed a license agreement with Magenta Therapeutics, a new startup company launched in Cambridge, for a portfolio of technologies with the potential to transform blood stem cell transplants from a “treatment of last resort” into a safer, more efficient therapy for patients with blood diseases...

Read more about HSCI research inspires startup

HSCI Matching Challenge Update

October 26, 2016

The Harvard Stem Cell Institute (HSCI) is pleased to announce the success of the 2015–16 General Fund Matching Challenge. Throughout fiscal year 2016, HSCI saw an outpouring of unrestricted funding, resulting in $2.6 million in new gifts and pledges. This support came from over 110 donors...

Read more about HSCI Matching Challenge Update